Five Prime Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Five Prime Therapeutics generated cash of -$64,654,000, which is more than the previous year. Cash used in financing activities reached the amount of $188,905,000 last year. Net change in cash is therefore $13,622,000.
Cash Flow
| 2011 | 23.28M | -27.00M | 26K |
|---|---|---|---|
| 2012 | -18.39M | 18.51M | 6.90M |
| 2013 | -25.33M | -42.18M | 64.28M |
| 2014 | 15.26M | -69.36M | 61.20M |
| 2015 | 289.09M | -238.23M | 83.84M |
| 2016 | -79.75M | -53.71M | -8.85M |
| 2017 | -112.18M | 174.20M | -9.88M |
| 2018 | -122.51M | -2.49M | 109.17M |
| 2019 | -113.86M | 126.17M | -463K |
| 2020 | -64.65M | -110.62M | 188.90M |
FPRX Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 57.34M | 45.49M | 61.33M | 7.65M | 149.97M | 15.26M | 8.16M | 11.39M | 4.36M | 8.05M |
Operating activities | ||||||||||
Net income | -84.32M | -137.20M | -140.44M | -150.22M | -65.69M | 249.64M | -37.42M | -28.87M | -27.59M | 19.71M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 5.90M | 5.31M | 5.02M | 2.51M | 1.74M | 1.67M | 1.55M | 1.69M | 1.64M | 1.63M |
Stock-based compensation expense | 10.18M | 22.81M | 29.46M | 34.17M | 32.88M | 11.46M | 3.41M | 2.14M | 1.72M | 2.92M |
| Deferred income tax benefit | 10.18M | 22.81M | 29.46M | 34.17M | 32.88M | 11.46M | 3.41M | 2.14M | 1.72M | 2.92M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 4.01M | 999K | 8.03M | -9.17M | 95K | -3.64M | -114K | 101K | 449K | -846K |
Inventories | -5.94M | -262.00M | -267.98M | -394.11M | -447.44M | -128.59M | -64.42M | -63.95M | 0 | 0 |
Accounts payable | -685K | -72K | -265K | 1.90M | -1.56M | 798K | 701K | -209K | -2.98M | 2.27M |
Cash generated by operating activities | -64.65M | -113.86M | -122.51M | -112.18M | -79.75M | 289.09M | 15.26M | -25.33M | -18.39M | 23.28M |
Investing activities | ||||||||||
Purchases Of Investments | -286.32M | -193.06M | -377.36M | -330.36M | -516.75M | -458.05M | -158.67M | -79.77M | -45.41M | -71.77M |
Investments In Property Plant And Equipment | -56K | -1.77M | -11.33M | -4.94M | -2.96M | -2.42M | -1.64M | -807K | -737K | -970K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -110.62M | 126.17M | -2.49M | 174.20M | -53.71M | -238.23M | -69.36M | -42.18M | 18.51M | -27.00M |
Financing activities | ||||||||||
Common Stock Issued | 170.35M | 0 | 107.61M | 4.02M | 0 | 78.69M | 58.72M | 63.84M | 105K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -2.35M | -1.59M | -2.40M | -13.90M | -14.05M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -9K | -15K | -13K |
Cash used in financing activities | 188.90M | -463K | 109.17M | -9.88M | -8.85M | 83.84M | 61.20M | 64.28M | 6.90M | 26K |
Net Change In Cash | 13.62M | 11.84M | -15.83M | 52.13M | -142.31M | 134.70M | 7.10M | -3.23M | 7.03M | -3.69M |
Cash at end of period | 70.96M | 57.34M | 45.49M | 59.79M | 7.65M | 149.97M | 15.26M | 8.16M | 11.39M | 4.36M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |